Literature DB >> 12469144

Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder.

Qing-You Kong1, Jia Liu, Xiao-Yan Chen, Xiao-Wei Wang, Yuan Sun, Hong Li.   

Abstract

Recurrence due to invasive growth is the major risk factor of transitional cell carcinoma (TCC) of urinary bladder. The interactions of hyaluronic acid (HA) and its receptors, CD44 and RHAMM, on cancer cells can promote invasion and metastasis but parallel study on these two genes in TCCs has not been available. The current work is aimed to address this issue by frozen tissue array-based immunocytochemical staining and Western blot hybridization. The results revealed that 19 out of 28 non-cancerous mucosa (68%) expressed CD44, in which 9 (33%) harbored variant exon 6 (v6). CD44 and v6 were both 5/11 (46%) in papillary, non-invasive carcinomas (pTa) and 6/14 (43%) in the tumors remained in sub-epithelial layer (pT1), while 5/29 (17%) and 3/29 (10%) in pT2-4 invasive tumors. RHAMM expression was uncommon in non-cancerous mucosa (5/28) but became frequent in pTa (9/11), pT1 (12/14) and pT2-4 (24/29) tumors. RHAMM proteins were labeled intracellularly and showed more than one isoforms. Our data further confirm the promising prognostic value of CD44 for TCC patients and demonstrate, for the first time, the correlation between RHAMM expression and malignant transformation of urothelial cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469144

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  Identification of genes correlated with early-stage bladder cancer progression.

Authors:  Randolph Stone; Anita L Sabichi; Jennifer Gill; I-Ling Lee; Patrick Adegboyega; Michael S Dai; Raja Loganantharaj; Marjan Trutschl; Urska Cvek; John L Clifford
Journal:  Cancer Prev Res (Phila)       Date:  2010-05-25

2.  Mechanism of MTA1 protein overexpression-linked invasion: MTA1 regulation of hyaluronan-mediated motility receptor (HMMR) expression and function.

Authors:  Deivendran Sankaran; Suresh B Pakala; Vasudha S Nair; Divijendra Natha Reddy Sirigiri; Dinesh Cyanam; Ngoc-Han Ha; Da-Qiang Li; T R Santhoshkumar; M Radhakrishna Pillai; Rakesh Kumar
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

3.  Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis.

Authors:  Mario W Kramer; Diogo O Escudero; Soum D Lokeshwar; Roozbeh Golshani; Obi O Ekwenna; Kristell Acosta; Axel S Merseburger; Mark Soloway; Vinata B Lokeshwar
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

4.  Expression patterns of CD168 correlate with the stage and grade of squamous cell carcinoma of head and neck.

Authors:  Korinna Jöhrens; Ioannis Anagnostopoulos; Steffen Dommerich; Jan Dirk Raguse; Agnieszka J Szczepek; Frederick Klauschen; Katharina Stölzel
Journal:  Mol Clin Oncol       Date:  2017-02-13

Review 5.  Hyaluronan: genetic insights into the complex biology of a simple polysaccharide.

Authors:  John A McDonald; Todd D Camenisch
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

6.  Development and validation of H11B2C2 monoclonal antibody-reactive hyaluronic acid binding protein: overexpression of HABP during human tumor progression.

Authors:  Rajeev K Boregowda; Hitesh N Appaiah; Mortha Karunakumar; Shivanna Parameshwariah; Geetha Avadani; Sunila Sunila; Shibdas Banerjee
Journal:  Tumour Biol       Date:  2012-10-26

Review 7.  Hyaluronan and hyaluronidase in genitourinary tumors.

Authors:  Melanie A Simpson; Vinata B Lokeshwar
Journal:  Front Biosci       Date:  2008-05-01

8.  Prognostic impact of CD168 expression in gastric cancer.

Authors:  Sumiya Ishigami; Shinichi Ueno; Yuka Nishizono; Masataka Matsumoto; Hiroshi Kurahara; Takaaki Arigami; Yasuto Uchikado; Tetsuro Setoyama; Hideo Arima; Kita Yoshiaki; Yuko Kijima; Masaki Kitazono; Shoji Natsugoe
Journal:  BMC Cancer       Date:  2011-03-24       Impact factor: 4.430

Review 9.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

10.  The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder.

Authors:  Christian Niedworok; Inga Kretschmer; Katharina Röck; Frank Vom Dorp; Tibor Szarvas; Jochen Heß; Till Freudenberger; Ariane Melchior-Becker; Herbert Rübben; Jens W Fischer
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.